Vistagen Taps Veteran Neuropsychiatry Exec as CMO to Advance Pherine Pipeline
Event summary
- Vistagen appointed Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026.
- Dr. Angelov brings 20 years of experience in clinical development and medical affairs from roles at Karuna, Neurocrine, Novartis, and Teva.
- Vistagen granted Dr. Angelov an incentive option to purchase up to 150,000 shares of common stock, vesting over 36 months.
- Vistagen's pherine product candidates include fasedienol (Phase 3 for social anxiety disorder), itruvone (major depressive disorder), and refisolone (menopause symptoms).
The big picture
Vistagen's appointment of Angelov reflects the growing emphasis on specialized medical leadership in neuroscience startups. The move comes as competitors like Karuna (now part of Bristol Myers Squibb) and Neurocrine Biosciences intensify focus on neuropsychiatric indications. With three pherine candidates in development, Vistagen aims to differentiate itself through non-systemic delivery mechanisms, potentially offering safer alternatives to existing treatments.
What we're watching
- Pipeline Acceleration
- How Dr. Angelov's expertise will impact the timeline for Vistagen's Phase 3 fasedienol trial and other pherine candidates.
- Strategic Fit
- Whether Angelov's background in neuropsychiatry aligns with Vistagen's expansion into women's health indications.
- Talent Retention
- The pace at which Vistagen can attract and retain top medical leadership to support its late-stage clinical pipeline.